New Leaf Venture Partners, L.L.C. — 13F Portfolio

New Leaf Venture Partners, L.L.C. (often referred to simply as New Leaf) is a specialized life sciences venture capital firm headquartered in New York, NY. The franchise traces its roots to the healthcare team of Sprout Group and was established as an independent platform to focus on building and financing innovative companies across biotechnology, pharmaceuticals, medical devices, diagnostics, and healthcare technology. The firm manages a series of venture and growth-oriented funds for institutional investors, endowments, foundations, and family offices. Capital is deployed globally but with a strong emphasis on U.S. and European life sciences hubs. New Leaf typically invests across stages—from early clinical development through later-stage and pre-commercial opportunities—and may continue to hold positions as portfolio companies transition into the public markets. New Leaf Venture Partners, L.L.C. appears in U.S. regulatory records as an institutional investment manager under CIK #0001631614 and files quarterly Form 13F with the U.S. Securities and Exchange Commission. These filings disclose the firm’s reportable long positions in U.S.-listed equities and certain equity-linked securities, primarily small- and mid-cap biopharmaceutical companies and, selectively, larger life-science tools and healthcare technology issuers. The 13F data cover only the public segment of a broader portfolio heavily weighted toward private companies. On an advanced analytics platform, this disclosure history can be organized into a New Leaf–specific Historical Track Record, normalized to any user-defined notional, allowing analysis of the capital trajectory implied by the disclosed sleeve.

New Leaf’s core strategy is science-driven venture and growth investment in life sciences. The firm seeks to finance companies that can deliver transformative therapies or enabling technologies, with a focus on areas such as oncology, immunology, neurology, rare and orphan diseases, and cutting-edge platform technologies. Key elements of the investment process include: - Rigorous scientific diligence on targets and mechanisms of action, often drawing on external KOLs and internal domain expertise. - Assessment of clinical-development plans, regulatory pathways, and competitive landscapes, including potential label breadth and lifecycle-management options. - Evaluation of management teams and syndicate composition, emphasizing experienced leadership and alignment with long-term value creation. - Capital-structure and financing planning, ensuring sufficient runway through critical data readouts and regulatory milestones. The firm participates in private rounds, crossover financings, and, in select cases, post-IPO capital raises. The positions visible in Form 13F generally fall into three categories: - Legacy holdings in companies that New Leaf backed privately and has continued to own following IPOs or other listing events. - Public investments in later-stage or de-risked biotechs and life-science tools companies where the team has high conviction in medium- to long-term upside. - Occasional anchors in larger-cap healthcare names that provide liquidity and strategic context around the core emerging-growth bets. Viewed through 13F Portfolio Composition, the book is typically concentrated in a finite number of issuers, heavily weighted toward therapeutics developers and, to a lesser extent, life-science tools and healthcare IT. Use of broad, non-sector ETFs is minimal; exposures are primarily company-specific and tied directly to scientific and clinical theses. Turnover in the public sleeve is low, as the firm generally holds through pivotal trial results and regulatory decisions, adjusting exposure mainly around major fundamental inflection points or fund-life considerations.

New Leaf Venture Partners, L.L.C. functions as the public-markets disclosure point for a specialized life sciences venture platform. Its 13F filings under CIK #0001631614 reveal a concentrated portfolio of U.S.-listed biotechnology and life-science tools companies that generally represent extensions of private investment theses rather than independent public-equity trades. For allocators and researchers, systematic analysis of New Leaf’s 13F Portfolio Composition over time is the most informative approach. Tracking how exposure shifts between therapeutic areas, development stages, and market-cap tiers through different biotech funding and regulatory cycles can illuminate the firm’s conviction and pacing in public markets. By feeding these disclosures into a Portfolio Simulator or other Performance Backtests Online, users can construct a normalized Historical Track Record, overlay the evolving Volatility Profile, and estimate an implied Sharpe Ratio for the disclosed sleeve. A central diagnostic question is how dynamically New Leaf adjusts its mix of public holdings—by issuer concentration, development-stage balance, and emphasis on higher-risk programs versus more derisked assets—as regimes rotate between biotech booms, capital-scarce environments, shifts in regulator posture, and broader equity-market stress, and how clearly those shifts are reflected in the capital path implied by its reported holdings.

The risk profile implied by New Leaf Venture Partners’ disclosed holdings is that of a concentrated, sector-specialist investor in high-uncertainty, high-upside healthcare assets. Several risk dimensions are particularly noteworthy: - Clinical and regulatory event risk: Many portfolio companies are in clinical development with limited or no current revenues. Pivotal trial outcomes, safety signals, or regulatory decisions can cause large price discontinuities. - Single-name concentration: A small group of core positions often represents a substantial share of reported exposure, magnifying the impact of idiosyncratic developments at those companies. - Sector and style exposure: The portfolio is almost entirely within biotechnology and life sciences, with an inherent growth and long-duration bias. Changes in discount rates, funding conditions for early-stage healthcare, or sentiment toward biotech as an asset class can drive significant cyclicality. Because Form 13F shows only long U.S.-listed holdings, it does not capture any risk-mitigating tools New Leaf may use—such as options, index hedges, or cash management—nor does it include non-U.S.-listed or private positions that can diversify risk. Nonetheless, by linking successive 13F filings and treating positions as held between quarter-ends (subject to observed changes), a holdings-based engine can reconstruct a synthetic long-only series for the public-biotech sleeve and estimate its Volatility Profile. This profile is typically elevated relative to broad equity indices and more akin to focused biotech or healthcare innovation benchmarks, with sharp drawdowns in sector-wide risk-off episodes and strong rebounds when sentiment or data flows are favorable. On a normalized notional basis, the same reconstructed series can be used to derive an implied Sharpe Ratio, providing a stylized measure of how effectively New Leaf’s stock selection and holding discipline in the public sleeve have historically converted substantial volatility into risk-adjusted compounding—recognizing that the majority of investor value is created in private rounds not visible in 13F.